MTOR and neoplasm: Unresolved challenges to researchers include: definition of the optimal dose and scheduling; identifying the appropriate biological end points for dose finding studies; finding predictive markers for tumour phenotypes likely to response to mTOR inhibitors; and finding optimal combination treatment with other drugs and radiotherapy.